<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03336814</url>
  </required_header>
  <id_info>
    <org_study_id>2017-07</org_study_id>
    <secondary_id>2017-000441-43</secondary_id>
    <nct_id>NCT03336814</nct_id>
  </id_info>
  <brief_title>Evaluation of Early Association of Terlipressin and Norepinephrine During Septic Shock; the TerliNor Study</brief_title>
  <acronym>TERLINOR</acronym>
  <official_title>Evaluation of Early Association of Terlipressin and Norepinephrine During Septic Shock; the</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In guidelines norepinephrine is the first line vasopressor recommended in case of septic
      shock. Use of vasopressin is recommended when norepinephrine fails to maintain a mean
      arterial pressure above 65mmHg or in salvage. Several studies failed to show a superiority of
      vasopressin over norepinephrine but none evaluated the effect of an early association on
      organ failure. Terlipressin is a pro-drug of vasopressin which has the same vasoconstrictor
      effect. We hypothesize that the early association of terlipressin and norepinephrine during
      septic shock reduces organ failure.

      This bi centric, double-blinded, randomised, controlled versus placebo study includes 40
      patients. Randomisation will be stratified between centers (two university affiliated
      intensive care units of Assistance-Publique-Hôpitaux de Marseille, Marseille, France). All
      patients with septic shock needing more than 0,5µg/kg/min of norepinephrine to reach PAM
      objectives are randomised, after hemodynamic evaluation and optimisation, to receive
      continuous infusions of terlipressin (0,01mg/kg/min) or placebo (physiologic serum). The 2
      groups receive steroid therapy (continuous intravenous hydrocortisone perfusion) at this
      time. Clinicians are blinded of perfusion used. Use of terlipressin remains possible in
      salvage when patients need more of 1µg/kg/min of norepinephrine on physician's decision.
      Patients with acute ischemic or septic heart failure are excluded of the study.

      Primary objective is sepsis related Sequential Organ Failure Assessment (SOFA) score
      difference between the groups at day 3. Secondary objectives are mortality at day 28,
      lactates clearance in the first 48hours, renal function (evaluates with AKIN criteria) and
      use of renal replacement therapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) score difference between the groups</measure>
    <time_frame>Day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactates clearance</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>terlipressin associated with norepinephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo (physiologic serum) associated with norepinephrine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>Administration of terlipressine</description>
    <arm_group_label>terlipressin associated with norepinephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of placebo</description>
    <arm_group_label>placebo (physiologic serum) associated with norepinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 18 years

          -  Dose of norepinephrine greater than 0.5 μg / kg / min

          -  Lactate greater than 2.0 mmol / l

        Exclusion Criteria:

          -  A left heart failure objectified in ultrasound transthoracique by a fraction of
             left(awkward) ejection of the ventricle lower than 30 % either by thermodilution
             transpulmonaire with a cardiac index lower than 2,5 l / min / m2 after optimization of
             the volémie or a central venous saturation in oxygen ( SVcO2) lower than 60 % after
             optimization of the blood volume.

          -  Minors

          -  Pregnant

          -  Not having terlipressin allergy

          -  Not having excipient allergy

          -  A history known for recent acute coronary syndrome (&lt; 3mois)

          -  An acute coronary syndrome defined by an increase of the troponine and a rise of the
             segment ST in the electrocardiogram
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Olivier ARNAUD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary Duclos</last_name>
    <email>gary.duclos@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Camille Delannoy</last_name>
    <phone>0491382747</phone>
    <phone_ext>+33</phone_ext>
    <email>drci@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Marseille</name>
      <address>
        <city>Marseille Cedex 05</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Terlipressin</keyword>
  <keyword>norepinephrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

